CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.

Related Keywords

Katherine Anne Gioia ,Ericl Smith ,Renier Brentjens ,Emily Henderson ,Roswell Park Comprehensive Cancer Center ,Dana Farber Cancer Institute ,Memorial Sloan Kettering Cancer Center ,New England Journal ,Cell Therapy Engineering Facility ,Deputy Director ,Katherine Anne Gioia Endowed Chair ,Cancer Medicine ,Roswell Park ,Sham Mailankody ,Cart Cell ,Fell ,Multiple Myeloma ,Myeloma ,T Cell ,Ntigen ,Flood ,Dancer ,Children ,Chimeric Antigen Receptor ,Clinical Trial ,Hospital ,Immune System ,Manufacturing ,Medicine ,Ncology ,Protein ,Eceptor ,Research ,Humor ,